CJC-1295 (without DAC)

Price and cost-per-mg comparison

CJC-1295 without DAC — commonly called Mod GRF 1-29 — is a synthetic, truncated (1-29) growth hormone-releasing hormone (GHRH) analog. Unlike the DAC variant, it does not carry the albumin-binding Drug Affinity Complex, so its effective half-life is measured in minutes rather than days. It binds pituitary GHRH receptors and, in research contexts, is associated with short, pulsatile stimulation of growth hormone secretion that more closely mimics the body's natural GH rhythm. The distinction from the DAC form is central and is why PeptideBase catalogs them as separate records. The DAC form (CJC-1295 DAC) binds circulating albumin and produces multi-day, sustained GHRH-receptor signaling; the non-DAC form here acts for only about half an hour, producing brief discrete pulses. Researchers describe them as different pharmacokinetic tools rather than interchangeable versions of one compound. The indexed human evidence base for the non-DAC form is very limited and largely mechanistic. CJC-1295 without DAC has no FDA approval and no approved therapeutic indication in any jurisdiction — it is available only as a research compound, and no Phase 2 or Phase 3 efficacy data exists for any specific application. Content here is educational and for research context only; it is not medical, dosing, or treatment guidance. [Women's health addendum] No controlled human data exist for CJC-1295 in any women's-health context; the only female-specific usage information is qualitative forum/netnography research, not clinical evidence. The original human pharmacokinetic trial was conducted in non-menopausal healthy adults and did not evaluate menopausal or reproductive endpoints. CJC-1295 is an unapproved research compound with no human pregnancy/lactation safety data.

104 listings · 66 vendors · updated 28 Sept 2026 · how prices are computed · educational only, not medical advice